Chronic total occlusions (CTOs) are not uncommon in catheterization laboratory practice and are considered as high-risk complex cases. The clinical benefit of percutaneous coronary intervention (PCI) for CTO remains controversial.
1,2 PCI may provide prognostic benefit in accurately selected patients with CTO; however, routine treatment with PCI may not be useful and may even be harmful in most cases. 2 Recently, Kranjec et al 3 concluded that performing a successful CTO PCI may be associated with similar clinical outcomes in patients with single-vessel non-CTO successful PCI and provides better long-term clinical outcomes compared with patients in whom CTO PCI failed. On the other hand, patients undergoing CTO PCI carry a risk of hazardous complications that may affect prognosis, irrespective of procedure success. 2 Therefore, some important issues should be clearly addressed before deciding to perform PCI in patients with CTO.
Unsuccessful CTO PCI is associated with higher frequency of periprocedural serious complications including erythrocyte transfusions, tamponade, and stroke and is associated with higher incidence of major adverse cardiovascular events (MACEs) and mortality. 2 Importantly, since the Occluded Artery Trial demonstrated that PCI did not reduce the longterm occurrence of MACE and mortality in stable patients with CTO, 4 there is no robust evidence indicating superiority of routine PCI over optimal medical therapy in patients with CTO. Another option may be surgical revascularization; however, the literature on prognostic value of surgical revascularization of isolated CTO is also limited. Nevertheless, coronary artery bypass graft surgery may be the best revascularization option in terms of improvement in clinical outcomes in selected patients with CTO and with left main coronary artery disease, multivessel disease, and viable myocardium. 5, 6 Additionally, in the absence of a large burden of ischemia or viable myocardium, there is lack of evidence regarding prognostic benefit of CTO PCI. 7 Therefore, in the study by Kranjec et al, 3 arbitrary patient selection and failed CTO PCI-related adverse events may have an effect on higher frequency of MACE, irrespective of revascularization.
Also, PCI seems to be unsuccessful in terms of improving the clinical outcomes of many patients with stable coronary artery disease compared with optimal medical therapy. 8 Hence, prognostic value of successful and failed CTO PCI should be compared with optimal medical therapy. The authors 3 should provide information regarding treatment with essential medications and optimal medical therapy for each group.
In conclusion, CTO PCI may improve the clinical outcomes in carefully selected patients. However, it is a high-risk intervention, and the predictors of improvement in clinical outcomes should be investigated more comprehensively before the procedure. In the absence of predictors of improvement in clinical outcomes, this procedure may not be useful, and failed CTO PCI may cause adverse outcomes irrespective of revascularization.
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